Experts discuss the rapid advancements in BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma, highlighting improved response rates and treatment integration.
Differentiating BCMA Bispecific Antibodies in R/R Multiple Myeloma: Real-World Integration and Patient-Centered Management
Explore the differences between bispecific antibodies and CAR T-cell therapy, highlighting their unique benefits and administration processes in cancer treatment.
Advertisement
Advertisement
Trending on CancerNetwork
1
Daratumumab Combo Yields Significantly Higher MRD Negativity in Multiple Myeloma
2
FDA Grants BTD to T-DXd in HER2+ BC With Residual Invasive Disease Post NAT
3
FDA Approves Subcutaneous Mosunetuzumab in R/R Follicular Lymphoma
4
JSKN003 Earns FDA Breakthrough Therapy Designation for HER2-Expressing PROC
5